arexvy rsv - Search News

News

GSK, RSV and European Medicines Agency

Reuters on MSN · 1d

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

Yahoo Finance · 1d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month,

Pharmabiz · 15h

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha

1d

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Moderna's RSV shot gets US nod for use in younger adults

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results